Phosphoproteome modifications and cortical circuit dysfunction are linked to the early-stage progression of alpha-synuclein aggregation.
This study demonstrates that early-stage alpha-synuclein aggregation in the cortex drives circuit dysfunction and non-motor symptoms in Parkinson's disease models through specific phosphoproteomic alterations, particularly involving ERK signaling and kinase-mediated pathways, rather than global changes in protein or lipid levels.